These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 26330133)

  • 1. Translating predictive biomarkers within oncology clinical development programs.
    Beckman RA; Chen C
    Biomark Med; 2015; 9(9):851-62. PubMed ID: 26330133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient, Adaptive Clinical Validation of Predictive Biomarkers in Cancer Therapeutic Development.
    Beckman RA; Chen C
    Adv Exp Med Biol; 2015; 867():81-90. PubMed ID: 26530361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.
    Tan DS; Thomas GV; Garrett MD; Banerji U; de Bono JS; Kaye SB; Workman P
    Cancer J; 2009; 15(5):406-20. PubMed ID: 19826361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Personalized Medicine: Genomics Trials in Oncology.
    Hayes DF; Schott AF
    Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging Biomarkers in the Era of Personalized Cancer Medicine.
    Ricciuti B; Leonardi GC; Brambilla M
    Dis Markers; 2019; 2019():5907238. PubMed ID: 31485277
    [No Abstract]   [Full Text] [Related]  

  • 6. Exceptional Responders Inspire Change: Lessons for Drug Development From the Bedside to the Bench and Back.
    Chau NG; Lorch JH
    Oncologist; 2015 Jul; 20(7):699-701. PubMed ID: 26040619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translating cancer genomes and transcriptomes for precision oncology.
    Roychowdhury S; Chinnaiyan AM
    CA Cancer J Clin; 2016; 66(1):75-88. PubMed ID: 26528881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers for personalized medicine in GI cancers.
    Zhang SY; Zhang SQ; Nagaraju GP; El-Rayes BF
    Mol Aspects Med; 2015 Nov; 45():14-27. PubMed ID: 26054566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive biomarkers for personalised anti-cancer drug use: discovery to clinical implementation.
    Alymani NA; Smith MD; Williams DJ; Petty RD
    Eur J Cancer; 2010 Mar; 46(5):869-79. PubMed ID: 20138504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The breakthrough of personalized medicine, new hopes and new challenges].
    Flippot R; Massard C; Auclin E; Azria D; Bourien H; Rochigneux P; Schernberg A; Verlingue L; Zafrani L; Vignot S
    Bull Cancer; 2017 Sep; 104(9):735-743. PubMed ID: 28807365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How Imaging Biomarkers Can Inform Clinical Trials and Clinical Practice in the Era of Targeted Cancer Therapy.
    Farwell MD; Clark AS; Mankoff DA
    JAMA Oncol; 2015 Jul; 1(4):421-2. PubMed ID: 26181243
    [No Abstract]   [Full Text] [Related]  

  • 12. Practice innovation: the need for nimble data platforms to implement precision oncology care.
    Elfiky A; Zhang D; Krishnan Nair HK
    Discov Med; 2015; 20(108):27-32. PubMed ID: 26321084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statistical aspect of translational and correlative studies in clinical trials.
    Pang H; Wang X
    Chin Clin Oncol; 2016 Feb; 5(1):11. PubMed ID: 26932435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An integrated framework for reporting clinically relevant biomarkers from paired tumor/normal genomic and transcriptomic sequencing data in support of clinical trials in personalized medicine.
    Nasser S; Kurdolgu AA; Izatt T; Aldrich J; Russell ML; Christoforides A; Tembe W; Keifer JA; Corneveaux JJ; Byron SA; Forman KM; Zuccaro C; Keats JJ; Lorusso PM; Carpten JD; Trent JM; Craig DW
    Pac Symp Biocomput; 2015; ():56-67. PubMed ID: 25592568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Translating biomarkers to clinical practice.
    Perlis RH
    Mol Psychiatry; 2011 Nov; 16(11):1076-87. PubMed ID: 21709685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Translating Immuno-oncology Biomarkers to Diagnostic Tests: A Regulatory Perspective.
    Li Y; Veeraraghavan J; Philip R
    Methods Mol Biol; 2020; 2055():701-716. PubMed ID: 31502175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New evidence-based adaptive clinical trial methods for optimally integrating predictive biomarkers into oncology clinical development programs.
    Beckman RA; Chen C
    Chin J Cancer; 2013 May; 32(5):233-41. PubMed ID: 23489587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coverage With Evidence Development and Managed Entry in the Funding of Personalized Medicine: Practical and Ethical Challenges for Oncology.
    Lewis JR; Kerridge I; Lipworth W
    J Clin Oncol; 2015 Dec; 33(34):4112-7. PubMed ID: 26460298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Translational bioinformatics and systems biology approaches for personalized medicine.
    Yan Q
    Methods Mol Biol; 2010; 662():167-78. PubMed ID: 20824471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Biomarkers on Personalized Medicine.
    Carrigan P; Krahn T
    Handb Exp Pharmacol; 2016; 232():285-311. PubMed ID: 26330258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.